GenScript ProBio

Established in 2021 and based in Nanjing, China, GenScript ProBio is a subsidiary of GenScript Biotech Corporation. The company was established as a CDMO platform integrating discovery, pre-clinical, and clinical development services for biologics and gene therapies. It has expanded operations globally with branches in the United States, the Netherlands, South Korea, Hong Kong, and Nanjing. Approximately half of its core research team holds doctoral degrees.

The company’s CEO, Husheng Min, formerly served as Chief Scientist at Amgen and led the establishment of Samsung Bio. In November 2021, its Nanjing antibody-protein production site passed the EU Qualified Person (QP) quality audit, and in May 2022, the company entered into a partnership with Athenex. To date, GenScript ProBio has supported more than 90 investigational new drug (IND) approvals across the United States, Europe, and Asia Pacific. In April 2023, GenScript ProBio raised approximately USD 240 million in series C funding.

The company provides biopharmaceutical CDMO services for cell and gene therapy (CGT) drugs, vaccine and biologic drug discovery and antibody-protein drugs. CDMO services include cell line and analytical method development, host cell commercialization licensing, upstream and downstream process development, and clinical sample and commercial production. Its solutions include cell and gene therapy solutions, and biologics development solutions. Cell and gene therapy solutions include plasmid clinical, mRNA, lentivirus and adeno-associated virus filing total solutions, and linearized plasmids and mRNA production.

The company generates revenue through CDMO contracts, including process development, clinical material production, and commercial manufacturing services for global pharmaceutical and biotechnology clients. GenScript ProBio plans to expand its global GMP manufacturing capacity, strengthen its integrated CMC solutions, and accelerate partnerships in antibody, vaccine and gene therapy development.